TORONTO, ONTARIO--(Marketwire - May 29, 2012) - Trimel Pharmaceuticals Corporation (TSX:TRL) ("Trimel or "the Company") announced today it has completed a preliminary review of early data from the Company's ongoing Phase III clinical trial. The preliminary review of early data demonstrated that 79.9% of patients treated with CompleoTRT™ achieved an average serum testosterone ("AST") level within the normal range. These results exceed the threshold required by the US Food and Drug Administration ("FDA") to confirm the efficacy of a testosterone replacement product.

CompleoTRT™ is in development for the treatment of male hypogonadism, a condition that is estimated to affect more than 13 million men in the United States, with only 10 percent currently receiving treatment according to the latest epidemiological data.

The preliminary data was obtained from 139 hypogonadal patients who had completed 30 days treatment and laboratory analysis. Patients will be dosed for an additional 60 days and then be reanalyzed for a total of 90 days of treatment. Within the patient sample, 107 patients were treated with CompleoTRT™ on a twice-daily ("BID") dosing regimen, the balance on a three-time daily ("TID") regimen. After 30 days of CompleoTRT™ treatment, the BID and TID treatment groups, both independently and collectively, achieved a percentage of patients with AST levels that exceed the FDA efficacy threshold for a testosterone replacement product.

The study is ongoing and complete data, including statistical analysis for all patient groups, is expected to be available in the fourth quarter of 2012. The complete efficacy and safety data package will be included in the final study analysis and will be part of the New Drug Application that the Company expects to file with the FDA at the end of 2012 / early 2013.

"We are excited by the positive results reported from our preliminary review of the Phase III early study data; these results are in-line with internal expectations. The preliminary patient results seen at this meaningful time point in the progress of the study, supports the veracity of the predictive modelling that guided the development of the study protocol," said Bruce D. Brydon, Chairman and Chief Executive Officer. "We look forward to sharing this early positive data with prospective partners."

Mr Brydon also shared the following comment: "Our decision to review and analyze the in-process study data was supported by continued positive investigator feedback regarding the overall patient experience with CompleoTRT™. One of our key investigators, Dr. Jeffrey Rosen, offered the follow insight: "CompleoTRT™ is a promising option for men seeking testosterone replacement therapy. CompleoTRT™ works well for my patients in the study, even the most difficult to treat who did not like the other therapies. Patients report that they feel better on this investigational product as compared to previous therapy including topical and injectables."

About CompleoTRT™

CompleoTRT™ is designed to represent a significant advancement in the treatment of male hypogonadism, or low testosterone - commonly known as "Low T". CompleoTRT™'s unique delivery technology is designed to provide patients with the therapeutic effect of supplementing testosterone levels while doing so with a small amount of drug in the form of a bio-adhesive intranasal gel.

CompleoTRT™'s intranasal no-touch delivery system is designed to avoid the risk of accidental transfer (secondary transference) of testosterone to spouses or other family members, thus offering unique patient benefits and improved safety as compared to other currently marketed products indicated to treat "Low T". Moreover, CompleoTRT™ is designed to avoid the negative effects from first-pass metabolism on the product, liver, or both.

Since Trimel took over development in May 2009, CompleoTRT™ has been optimized to meet FDA regulatory requirements, including the development of a no-touch applicator device that is designed to ensure that CompleoTRT™ is dosed accurately and discretely. Trimel's research program to date has demonstrated that CompleoTRT™ is safe and effective, having recorded over 10,000 drug exposures in the studies conducted thus far in the United States.

About Hypogonadism ("Low T")

Subject to FDA approval, Trimel's lead product candidate, CompleoTRT™, would be indicated for the treatment of male hypogonadism or low testosterone - commonly known as "Low T." Hypogonadism is a biochemical syndrome characterized by a deficiency in serum testosterone levels that can be either acquired or inherited, and seriously affects the quality of life for those affected with the syndrome. Low testosterone is estimated to affect 13 million men in the United States, of which an estimated 90% go untreated. According to IMS Health, sales of marketed treatments for low testosterone in North America grew 24% in 2011 versus 2010 to now exceed $1.6 billion in annual sales volume.

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit [ www.trimelpharmaceuticals.com ].

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chairman of the Board and Chief Executive Officer at (416) 679-0711 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at [ ir@trimelpharmaceuticals.com ].

Notice regarding forward-looking statements:

This release contains forward looking information. This forward-looking information is not based on historical facts but rather on the expectations of the Company's management regarding the future growth of the Company and its respective results of operations, performance and business prospects and opportunities. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives or economic performance, or the assumptions underlying any of the foregoing. This release uses words such as "will", "expects", "anticipates", "intends", "estimates", or similar expressions to identify forward-looking information. Such forward-looking information reflects the current beliefs of the Company's management based on information currently available to them.

Forward-looking information included in this release is based in part, on assumptions that may change, thus causing actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking information. Such assumptions include that: the Company will achieve, sustain or increase profitability, and will be able to fund its operations with existing capital, and/or it will be able to raise additional capital to fund operations; the Company will be able to attract and retain key personnel; the Company will be able to acquire any necessary technology or businesses and effectively integrate such acquisitions; the Company will be successful in developing and clinically testing products under development; the Company will be successful in obtaining all necessary approvals for commercialization of its products from the U.S. Food and Drug Administration, the Canadian Therapeutic Products Directorate or other regulatory authorities; the results of continuing and future safety and efficacy studies by industry and government agencies relating to the Company's products will be favourable; the Company's products will not be adversely impacted by competitive products and pricing; raw materials and finished products necessary for the Company's products will continue to be available; the Company will be able to maintain and enforce the protection afforded by any patents or other intellectual property rights; the Company's products will be successfully licensed to third parties to market and distribute such products on favourable terms; the Company's key strategic alliances, out licensing and partnering arrangements, now and in the future, will remain in place and in force; the general regulatory environment will not change in a manner adverse to the business of the Company; the tax treatment of the Company and its subsidiaries will remain constant and the Company will not become subject to any material legal proceedings. The Company cautions that the foregoing list of assumptions is not exhaustive.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results, performance or achievement could differ materially from that expressed in, or implied by; any forward-looking information in this release, and, accordingly, investors should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made and the Company undertakes no obligation to update any forward-looking information to reflect the occurrence of unanticipated events, except as required by law including applicable securities laws. New factors emerge from time to time and the importance of current factors may change from time to time and it is not possible for management of the Company to predict all of such factors, changes in such factors and to assess in advance the impact of each such factor on the business of the Company or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information contained in this release.